Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5803 USD | -0.12% | -10.86% | -29.38% |
May. 30 | Brookline Capital Initiates Forte Biosciences at Buy Rating With $4 Price Target | MT |
May. 13 | Forte Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-29.38% | 21.15M | |
+16.73% | 121B | |
+13.68% | 107B | |
-5.57% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.30% | 15.31B | |
+3.16% | 14.08B | |
+25.25% | 11.74B |
- Stock Market
- Equities
- FBRX Stock
- News Forte Biosciences, Inc.
- Forte Biosciences : Brookline Capital Downgrades Forte Biosciences to Hold from Buy